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Biotransformation of acridine, dictamnine and 4-chlorofuro[2,3-b]quinolone, using whole cells of
Sphingomonas yanoikuyae B8/36, yielded five enantiopure cyclic cis-dihydrodiols, from biphenyl
dioxygenase-catalysed dihydroxylation of the carbocyclic rings. cis-Dihydroxylation of the furan ring in
dictamnine and 4-chlorofuro[2,3-b]quinoline, followed by ring opening and reduction, yielded two
exocyclic diols. The structures and absolute configurations of metabolites have been determined by
spectroscopy and stereochemical correlation methods. Enantiopure arene oxide metabolites of acridine
and dictamnine have been synthesised, from the corresponding cis-dihydrodiols. The achiral furoquinoline
alkaloids robustine, c-fagarine, haplopine, isohaplopine-3,39-dimethylallylether and pteleine have been
obtained, from either cis-dihydrodiol, catechol or arene oxide metabolites of dictamnine.
Introduction
Polycyclic azaarenes are ubiquitous in the environment as
atmospheric pollutants, resulting from incomplete combus-
tion of nitrogen-containing molecules present in fossil fuels or
tobacco and also as plant alkaloids.1a,b Some larger members
of the family of aza-polycyclic aromatic hydrocarbons (APAHs)
present a significant hazard to human health, resulting from
the mutagenicity/carcinogenicity of their mammalian metabo-
lites.1c–e The mineralization of APAHs and alkaloids contain-
ing azaaromatic rings by soil bacteria, via non-mutagenic/non-
carcinogenic metabolites can, therefore, play a useful role in
reducing this problem. Earlier bacterial studies from these
laboratories have focused on the toluene dioxygenase (TDO)-
catalysed biodegradation of bicyclic heterocycles including
quinolines,2a,b benzo[b]thiophenes2c and benzo[b]furans,2c
using the UV4 mutant strain of Pseudomonas putida
(Schemes 1a and 1b). Regioselective cis-dihydroxylation of
the carbocyclic and the heterocyclic rings in the quinolines
(5,6 and/or 7,8 and/or 2,3 bonds), benzo[b]thiophenes (4,5
and/or 2,3 bonds) and benzo[b]furans (6,7 and/or 2,3 bonds),
occurred to give the corresponding cis-dihydrodiol metabo-
lites. The 3-hydroxyquinoline and anthranilic acid metabolites
of quinoline were assumed to be derived from the undetected
heterocyclic cis-3,4-dihydrodiol intermediate (Scheme 1a).2a,b
Further metabolism of the benzo[b]furan 2,3-cis-diols involved
spontaneous ring opening and enzyme-catalysed carbonyl
reduction to give exocyclic phenolic diol products
(Scheme 1b).2c
Dihydroxylation of the 3,4-bond in the electron-deficient
pyridine ring of the quinoline substrates was found to yield
only minor metabolites in comparison with its carbocyclic 5,6-
and 7,8-bonds. However, when benzo[b]thiophene and ben-
zo[b]furan substrates, containing electron-rich heterocyclic
rings, were used as substrates, dihydroxylation of the 2,3-
bond revealed a more favourable metabolic route (Schemes 1a
and 1b).
The steric dimensions of the active site in TDO, expressed
in P. putida UV4, limited the acceptable size of substrates to
mono- or bi-cyclic arenes (Schemes 1a and 1b). However, the
biphenyl dioxygenase (BPDO) enzyme, present in the B8/36
mutant strain of Sphingomonas yanoikuyae, has a larger active
site and was able to accept tri-, and tetra-cyclic arenes (e.g.
benzo[f]quinoline, benzo[h]quinoline, phenanthridine,3a ben-
zo[c]phenanthridine,3b Scheme 2) as substrates. It is note-
worthy that in these examples a marked regioselective
preference for cis-dihydroxylation was found at a bond within
the bay-region.
As part of an earlier programme3b,c to investigate the ability
of BPDO to catalyse the cis-tetrahydroxylation of larger
polycyclic aromatic rings, it was found that bis-cis-dihydrodiols
were formed as further metabolites of the initial cis-dihydro-
diols derived from larger carbocyclic (e.g. anthracene, chry-
sene, benz[a]anthracene) and heterocyclic (e.g. acridine,
phenazine, benzo[b]naphtha[2,1-d]thiophene) substrates. The
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similarity in size and shape of the linear tricyclic arenes,
anthracene and acridine, and their acceptability as sub-
strates for the BPDO enzyme,3c,d prompted this comparative
biotransformation study of acridine with furo[2,3-b]quinoline
substrates. Following our earlier reports on the isolation and
synthesis4a–e of quinoline alkaloids, from plants of the
Rutaceae family, e.g. Choisya ternata, and Skimmia japonica,
linear furoquinolines (4-chlorofuro[2,3-b]quinoline and dic-
tamnine) were briefly examined as potential substrates, using
whole cells of S. yanoikuyae B8/36 expressing BPDO
enzyme.4d
In our preliminary studies of the biotransformations of
acridine and dictamnine, using S. yanoikuyae B8/36, we had
reported3d,4d the presence of the corresponding cis-dihydrodiol
metabolites. This comprehensive study now provides full
structural and stereochemical characterization of all new
bacterial metabolites and shows how they can be utilized in
Scheme 1
Scheme 2
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the chemoenzymatic synthesis of a wider range of animal and
plant metabolites, e.g. arene oxides and furoquinoline
alkaloids.
Results and discussion
(i) Biotransformation of acridine 1
The mammalian metabolism and mutagenicity of acridine 1
have been studied over many years using dog, rabbit and rat
liver cells.5a–d The major metabolites were found to be
2-hydroxyacridine, 9-acridone, 2-hydroxy-9-acridone and
trans-1,2-dihydroxy-1,2-dihydroacridine 3 (Scheme 3). It is
probable that trans-dihydrodiol 3 and 2-hydroxyacridine were
derived from the undetected acridine 1,2-oxide 2. The
identification of these mammalian metabolites of acridine 1,
which could be accounted for, mainly, by monooxygenase-
catalysed oxidation, prompted the preliminary3d and current
study of its dioxygenase-catalysed metabolism.
Biotransformation of acridine 1, using S. yanoikuyae B8/36
under similar conditions to those used for other azaarene
substrates,3a–d followed by extraction (EtOAc) and column
chromatography, yielded cis-dihydrodiol 4 ([a]D +71) in
acceptable yield (42%). The structure of cis-diol 4 was
determined by NMR, MS and elemental microanalysis. The
enantiomeric excess value (ee) was estimated as .98% by
reaction with (R)-(+)- and (S)-(2)-2-(1-methoxyethyl)phenyl-
boronic acid (MPBA) and 1H-NMR analysis of the resulting
boronates.
The absolute configuration of cis-dihydrodiol 4 was initially
assigned as (1R,2S), based on the well established 1H-NMR
pattern previously observed for MPBA derivatives from other
polycyclic arene cis-dihydrodiol metabolites (e.g. from
naphthalene, anthracene, phenanthrene and their aza-analo-
gues).2a,b,3a,b The observation of a larger chemical shift value
(dH 3.18) for the MeO group protons, using the (R)-(+)-MPBA
compared with the value obtained using (S)-(2)-MPBA (dH
3.11), was again assumed to be consistent with a benzylic (R)
and an allylic (S) configuration for cis-dihydrodiol 4. The
reliability of the MPBA method for the linear azaarene cis-
dihydrodiol 4 was confirmed by an unequivocal stereochemi-
cal correlation sequence similar to that used for other
polycyclic arene cis-dihydrodiols (Scheme 4).3a,6 The sequence
involved a catalytic hydrogenation (H2,Pd/C) to yield cis-
tetrahydrodiol 5 followed by bis-acetylation (Ac2O, pyridine)
to give cis-diacetate 6. In the final step, an oxidative ring
opening reaction (RuO2/NaIO4) gave a mixture of dicarboxylic
acid products (7/8). It was assumed that the bicyclic
dicarboxylic acid 7 was formed initially and then a part of it
degraded to acyclic dicarboxylic acid 8 via a further oxidative
ring opening reaction. The mixture of dicarboxylic acids 7 and
8 was methylated (CH2N2) to yield dimethylesters 9 and 10
which were separated by column chromatography. The minor
component, dimethyl(2,3-diacetoxy)adipate 10 ([a]D 214) was
of established (2S,3S) configuration6 and thus the (1R,2S)
configuration was unequivocally assigned to (+)-cis-dihydro-
diol 4.
It has been proposed that the mutagenicity/carcinogenicity
associated with some larger PAHs and APAHs results from: (i)
a monooxygenase-catalysed epoxidation of a carbocyclic ring
to yield an arene oxide (cf. compound 2), (ii) an epoxide
hydrolase-catalysed hydrolysis of the arene oxide to yield a
trans-dihydrodiol (cf. compound 3), (iii) a monooxygenase-
catalysed epoxidation of the alkene bond in the trans-
dihydrodiol to yield diastereoisomeric trans-diol epoxides
and (iv) nucleophilic attack of DNA on the epoxide ring within
a bay region to yield a covalent adduct.1b–f Although the
corresponding acridine trans-diol epoxides from metabolite 3
could, in principle, also be mutagens, their synthesis and
mutagenicity has not yet been reported.
(ii) Biotransformation of furoquinolines 11–13
In common with acridine 1, the mammalian metabolism and
mutagenicity of dictamnine 12 and other furoquinoline
alkaloids, e.g. c-fagarine, had been reported earlier.7a–e In a
more recent study, from these laboratories, the furoquinoline
Scheme 3
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alkaloid skimmianine 13 was found to be the major
compound present in C. ternata,4a and was thus available as
a potential substrate for the current biotransformation
studies. However, dictamnine 12, another furoquinoline
alkaloid required as a potential substrate, was not isolated
from C. ternata. Thus, a five-step chemical synthesis of
dictamnine 12 was carried out, starting from aniline and
using the literature procedure8a–c which involved 4-chlorofur-
oquinoline 11 as precursor. Furoquinolines 11 and 12 were
thus also available as possible substrates for BPDO.
Furoquinolines 11–13 were added, individually, as sub-
strates to S. yanoikuyae B8/36, under the conditions used
previously for the successful biotransformation of acridine 1.
The results, shown in Scheme 5, indicate that while
4-chlorofuro[2,3-b]quinoline 11 and dictamnine 12 each
yielded a mixture of two cis-dihydrodiol products 14–17,
resulting from BPDO-catalysed cis-dihydroxylation of the 5,6
and 7,8 bonds of the carbocyclic ring, skimmiamine 13 was
not an acceptable substrate. The mixtures of metabolites (14/
15 and 16/17) were separated into individual cis-dihydrodiols
by PLC purification. The structures of diol metabolites (14–17)
were established by analyses of NMR and MS data while the ee
values (.98%) and absolute configurations were again
determined by formation of the corresponding diastereomeric
MPBA esters and their analysis by 1H-NMR spectroscopy. As
found for the acridine cis-dihydrodiol 4, the larger chemical
shift values (dH) for the exocyclic MeO group of cis-dihydro-
diols 14–17, (dH 3.23–3.25) using the (R)-(+)-MPBA compared
with (S)-(2)-MPBA 14–17, (dH 3.19–3.20) were consistent with
benzylic (R) and allylic (S) configurations in each case.
While cis-dihydroxylation had occurred exclusively at the 1,2
bond of acridine 1, similar regioselectivity for the equivalent
Scheme 4
Scheme 5
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(5,6) bond in furoquinolines 11 and 12 was not found. A
modest preference (38% yield) was observed for BPDO-
catalysed cis-dihydroxylation at the 7,8-bond to form cis-diol
15 compared with the 5,6-bond (10% yield) to give cis-diol 14,
when 4-chlorofuro[2,3-b]quinoline 11 was the substrate. A
stronger preference for oxidation of the 7,8-bond was found
with dictamnine 12 as the substrate, which resulted in cis-diol
17 being the major metabolite (20–30% yield) relative to cis-
diol 16 (1–3% yield). The combined isolated yields (21–33%) of
dictamnine cis-dihydrodiols (16 and 17) were slightly lower
than 4-chlorofuroquinoline cis-dihydrodiols (14 and 15, 48%);
no cis-dihydrodiol metabolites were detected from skimmia-
nine 13 as substrate. These observations suggest that the
presence of substituents at C-4, C-7 and C-8 and the overall
steric requirements of the substrate within the active site of
the BPDO enzyme are important factors. Based on isolated
yields, it appears that cis-dihydroxylation occurred preferen-
tially at the less sterically hindered 7,8-bond and that the best
yields resulted from the use of the smaller substrates (11 and
12). As the largest substrate, skimmianine 13, did not yield cis-
diol metabolites, this is consistent with its failure to be
accommodated within the BPDO active site. However, alter-
native factors, including aqueous solubility, toxicity and
further metabolism, could influence the isolated yields of
bioproducts.
The most polar metabolites, formed from 4-chlorofuro[2,3-
b]quinoline 11 and dictamnine 12, were found to be exocyclic
diols (compounds 20 and 23) but were isolated in very low
yields (1–2%, Scheme 5). While the structures of optically
active diols 20 and 23 were assigned by NMR and MS
spectroscopic analysis, their ee values and absolute configura-
tions were not determined. It was assumed, that the exocyclic
diols 20 and 23, resulted from: (a) BPDO-catalysed cis-
dihydroxylation at the 2,3-bond to give transient intermediates
18 and 21, (b) reversible ring opening of these hemiacetals (cf.
mutarotation) to yield the undetected aldehydes 19 and 22, (c)
epimerization, following reversible ring closure, to yield a
mixture of the corresponding cis- and trans-dihydrodiols, and
(d) carbonyl reductase-catalysed (CRED) reduction of the
aldehyde group in intermediates 19 and 22. A similar sequence
of TDO-catalysed cis-dihydroxylation of the furan ring of
benzo[b]furans, spontaneous equilibration via a reversible
ring opening process to yield the corresponding phenolic
aldehydes and CRED-catalysed reduction of the resulting
aldehyde group was earlier assumed to account for the
isolation of the exocyclic diols shown in Scheme 1 (b).2c
The origin of mutagenicity associated with dictamnine 13
has not yet been rigorously established.7a–e However, it has
been proposed that, in common with other naturally occurring
mutagenic furans, e.g. aflatoxin B1 and 8-methoxypsoralen,
the corresponding transient furan epoxides,7f formed as initial
mammalian metabolites via monooxygenase-catalysed epox-
idation, e.g. arene oxide 24 (Scheme 5) may be responsible for
their mutagenicity. It has been proposed that the mutagenicity
results from the ability of furan epoxides to form covalently
bound adducts following nucleophilic ring-opening reactions
with DNA.7e,f
(iii) Application of acridine cis-dihydrodiol 4 in the synthesis
of arene oxide 2
As part of an earlier study of the mammalian metabolism and
mutagenicity/carcinogenicity of PAHs and APAHs, (1R,2S)-
arene oxide 2 was obtained via an eight stage chemical
synthesis, involving a chemical resolution of MTPA esters, with
an overall yield of ca. 13%.9 Alkaline hydrolysis (KOH, t-BuOH)
of (1R,2S)-arene oxide 2 gave the mammalian metabolite
(1R,2R)-trans-1,2-dihydroacridine-1,2-diol 3.9 In the current
study, the possibility of a much shorter synthesis of acridine
1,2-oxide 2 was examined (Scheme 6), using the readily
available bacterial metabolite, (1R,2S)-cis-1,2-dihydroacridine-
1,2-diol 4. Treatment of diol 4 with 1-bromocarbonyl-1-
methylethyl acetate, in acetonitrile solution, gave a mixture
of bromoacetates 25/26 whose structures were determined
from 1H-NMR and MS data. Due to their instability, during
attempted separation, the mixture of bromoacetates 25 and 26
in Et2O solution was reacted directly with NaOMe. Using this
two step method, the relatively stable (1R,2S)-arene oxide 2 was
synthesised from cis-dihydrodiol 4 in 66% yield. Despite the
stability of arene oxide 2, it was not detected during
mammalian metabolism, probably due to its further metabo-
lism via a rapid epoxide hydrolase-catalysed conversion to the
corresponding trans-dihydrodiol 3.5a–e A preliminary study3d
later showed that when the stable acridine cis-dihydrodiol 4
was used as a substrate for S. yanoikuyae B8/36, it was also
further metabolised and formed a bis-cis-dihydrodiol biopro-
duct.
(iv) Application of dictamnine cis-dihydrodiols 16 and 17 as
precursors in the synthesis of furoquinoline alkaloids
The potential of dictamnine cis-dihydrodiol metabolites 16
and 17 in the biomimetic synthesis of furoquinoline alkaloids,
including the proposed arene oxide intermediate 27, was of
biosynthetic interest (Schemes 7 and 8). Possible biosynthetic
pathways to furoquinoline alkaloids occurring in Rutaceaeous
plants, e.g. Skimmia japonica and Choisya ternata, have been
studied using 14C-labelled precursors.10a These labelling
studies showed that enzyme-catalysed hydroxylation could
Scheme 6
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occur on the benzene ring of dictamnine 12 to yield a wider
range of furoquinoline alkaloids e.g. skimmianine 13 and
possibly also robustine 30 and c-fagarine 31 (Scheme 7). It was
proposed that skimmianine 13 could be formed via a
monooxygenase-catalysed epoxidation of dictamnine 12, to
yield the transient arene oxide 27, followed by epoxide
hydrolase-catalysed hydrolysis to yield trans-dihydrodiol
28.10a The possibility of an alternative dioxygenase-catalysed
cis-dihydroxylation of dictamnine 12 to yield cis-dihydrodiol 17
was also discussed.10a The enzyme-catalysed oxidations of
trans- and cis-dihydrodiols, to yield catechols followed by
O-methylation, are well established metabolic steps1a and,
when allied to the earlier labelling studies,10a either type of
enzymatic oxidation could account for the formation of
catechol 29 and skimmianine 13. To date, none of the
potential biosynthetic intermediates 17, 27–29 have been
detected by the labelling studies using Choisya ternata10a or
found among the furoquinoline alkaloids recently isolated
from this4a or other plants in the Rutaceae family.10b
As expected, the B8/36 mutant strain of S. yanoikuyae did not
yield catechol metabolites e.g. compound 29 from dictamnine
12 (Scheme 7). The biphenyl cis-diol dehydrogenase (DD)
activity required to catalyse the dehydrogenation of cis-
dihydrodiols to yield catechols, was blocked in the B8/36
strain. However, when the wild type strain of S. yanoikuyae
(B1), expressing both BPDO and DD enzymes, was used with
dictamnine 12, the only metabolite identified and isolated was
cis-dihydrodiol 16, albeit in low yield (8%). This observation is
consistent with both cis-dihydrodiols 16 and 17 being formed
but the major metabolite (17) being further metabolized
preferentially.
The E. coli narB recombinant strain, expressing naphthalene
DD, has been used successfully to produce catechols in good
yields from the corresponding monocyclic arene cis-dihydro-
diols.11 Using E. coli narB and cis-dihydrodiol 15 as substrate,
catechol 35 was detected by 1H-NMR spectroscopy but in low
yield. Surprisingly, the required catechol metabolite 29,
derived from dictamnine cis-dihydrodiol 17, could not be
obtained using this method. However, it was possible to obtain
catechol 29 in good yield (85%) using boron tribromide for the
selective O-demethylation of skimmianine 13, isolated ear-
lier4a from Choisya ternata (Scheme 8).
Convincing evidence of monooxygenase-catalysed epoxida-
tion of dimethylallyl groups, and hydrolysis of the resulting
epoxides to yield vicinal diols, is available from biosynthetic
studies of quinoline alkaloids from plants of the Rutaceae
family.10a,b Furthermore, monooxygenase-catalysed epoxida-
tion of azaarenes, to yield the corresponding arene oxides, e.g.
quinoline 5,6-oxide from quinoline, using liver microsomes
with inhibition of epoxide hydrolase activity,12a,b provides a
precedent for the formation of the elusive dictamnine arene
oxide 27 and trans-dihydrodiol 28 metabolites. While the
dioxygenase-catalysed cis-dihydroxylation of polycyclic azaar-
enes in bacteria, e.g. S. yanoikuyae B8/36, is well established
(Schemes 1, 2 and 4), there appears to be little evidence of this
pathway occurring in plants. Consequently, the monooxygen-
ase-catalysed epoxidation sequence, shown in Scheme 7, is
currently favoured over the dioxygenase pathway. Epoxidation,
Scheme 7
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as an initial step, can readily account for the formation of both
monophenols (e.g. robustine 30), catechols (e.g. 7,8-dihydrox-
ydictamnine 29), and their methylated derivatives (e.g. c-
fagarine 31 and skimmianine 13).
Our attempt to synthesise the proposed dictamnine arene
oxide metabolite 27 from cis-dihydrodiol 17, via a two-step
process similar to that used earlier for acridine arene oxide 2
(Scheme 6), was unsuccessful. This was due to compound 17
being less stable under the reaction conditions and more
readily dehydrated under acid conditions to yield phenols (e.g.
robustine 30). An alternative approach (Scheme 8) was adopted
involving the catalytic hydrogenation (H2, Pd–C) of compound
17 to yield the stable cis-tetrahydrodiol 32 (76% yield).
Treatment of diol 32 with 1-bromocarbonyl-1-methylethyl
acetate gave trans-bromoacetate 33 in good yield (90%).
Benzylic bromination of bromoacetate 33 (NBS, CCl4) gave
an inseparable mixture of diastereoisomers 34 which was
immediately treated with sodium methoxide in THF, to yield
the proposed dictamnine arene oxide metabolite 27 (60% yield
from compound 33). Initial attempts to purify this elusive
arene oxide by PLC resulted in its aromatization to give the
furoquinoline alkaloid robustine 30. Purification of (7S,8R)-
dictamnine oxide 27 was achieved by careful crystallization. A
sample of oxide 27 was found to survive in CDCl3 solution
without decomposition, at ambient temperature over a 24 h
period.
In the final phase of this study, cis-dihydrodiols 16 and 17,
arene oxide 27 and catechol 29, as confirmed or proposed
metabolites of dictamnine 12, were utilized as synthetic
precursors of other furoquinoline alkaloids, using biomimetic
methods (Scheme 8). While robustine 30 was obtained by
isomerisation of arene oxide 27 under acidic conditions, the
acid-catalysed dehydration of cis-dihydrodiol 17 was the
preferred route. Methylation of robustine 30 with diazo-
methane yielded the alkaloid c-fagarine 31. Under similar
conditions, methylation of catechol 29 occurred mainly at C-8,
to yield the alkaloid haplopine 36. Treatment of catechol 29 in
acetone with 1-chloro-3-methylbut-2-ene in presence of K2CO3
resulted in the preferential prenylation at C-8 to yield phenol
37, which on methylation yielded the alkaloid, isohaplopine-
3,39-dimethylallylether 38. Acid-catalysed dehydration of cis-
dihydrodiol 16, to form phenol 39, followed by methylation,
yielded the furoquinoline alkaloid pteleine 40.
Conclusion
The bacterial cis-dihydroxylation of acridine 1 and furoquino-
lines 11 and 12, catalysed by BPDO, yielded five carbocyclic cis-
dihydrodiols, (4, 14–17) and two exocyclic diols (20 and 23),
derived from the transient heterocyclic diols 18 and 21. The
structures and absolute configurations of most of the isolated
metabolites were established by spectroscopic analysis and
Scheme 8
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stereochemical correlation methods. cis-Dihydrodiols 4 and 17
were used in the synthesis of the corresponding arene oxides,
2 and 27, which had been proposed as intermediates in
mammalian metabolism of acridine 1 and dictamnine 12. cis-
Dihydrodiol 16 and 17 and arene oxide 27, as derivatives of
dictamnine 12, have been used in the synthesis of a wide range
of furoquinoline alkaloids including robustine 30, c-fagarine
31, haplopine 36, isohaplopine-3,39-dimethylallylether 38 and
pteleine 40.
Experimental
1H and 13C NMR spectra were recorded on Bruker Avance 400,
DPX-300 and DRX-500 instruments. Chemical shifts (d) are
reported in ppm relative to SiMe4 and coupling constants (J)
are given in Hz. Mass spectra were run at 70 eV, on a VG
Autospec Mass Spectrometer, using a heated inlet system.
Accurate molecular weights were determined by the peak
matching method, with perfluorokerosene as the standard. CD
spectra were recorded in spectroscopic grade acetonitrile using
a JASCO J-720 instrument. A PerkinElmer 341 polarimeter was
used for optical rotation ([a]D) measurements (ca. 20 uC). Flash
column chromatography and preparative layer chromatogra-
phy (PLC) were performed on Merck Kieselgel type 60 (250–400
mesh) and PF254/366 plates respectively. Merck Kieselgel type
60F254 analytical plates were employed for TLC. Authentic
samples of 4-chlorofuro[2,3-b]quinoline 11 and skimmianine
13 were available from earlier studies.4a–e As reported,2b
Sphingomonas yanoikuyae B8/36 was grown on minimal salts
medium with 0.5% sodium succinate and 0.5 g L21 of yeast
extract. Biphenyl dioxygenase (BPDO) was induced, during the
exponential phase of growth, by the addition of m-xylene (1
cm3 L21) every 0.5 h for 7 h. Substrate concentration was 0.5
mg cm23.
Synthesis of dictamnine 12
To a solution of 4-chlorofuro[2,3-b]quinoline 11 (3 g, 14.7
mmol) in dry methanol (120 cm3) was added sodium
methoxide (4.05 g, 75 mmol) and the mixture refluxed (2 h)
under nitrogen. After removal of methanol from the reaction
mixture, under reduced pressure, the brown residue obtained
was treated with ice cold water and the aqueous mixture
extracted with chloroform (3 6 100 cm3). The combined
organic extract was dried (Na2SO4), concentrated under
reduced pressure, and the crude product purified by flash
chromatography (1 : 1, EtOAc : hexane) to afford dictamnine
12 as a yellow solid (1.65 g, 56%); Rf 0.5, (1 : 1 EtOAc/hexane);
m.p. 133–134 uC (lit.13a 132–133 uC); dH (300 MHz, CDCl3) 4.45
(3 H, s, Me), 7.08 (1 H, d, J3,2 2.8, 3-H), 7.45 (1 H, dd, J6,5 9.1, J6,7
7.0 6-H), 7.62 (1 H, d, J2,3 2.8, 2-H), 7.69 (1 H, dd, J7,8 8.4, J7,6 7.0
J 7.0, 7-H), 8.0 (1 H, d, J8,7 8.4, 8-H), 8.26 (1 H, d, J5,6 9.1, 5-H).
(a) Biotransformation of acridine 1
(1R,2S)-1,2-Dihydroacridine-1,2-diol 4. Biotransformation of
acridine 1 (15 g) using S. yanoikuyae B8/36 followed by
extraction with EtOAc yielded (1R,2S)-1,2-dihydroacridine-1,2-
diol 4 (7.5 g, 42%). The majority of the diol metabolite 4
crystallized out of solution on concentration. The mother
liquor was purified by column chromatography (CHCl3 A10%
MeOH/CHCl3). Colourless crystalline solid, m.p. 176 uC
(EtOH); Rf 0.45 (15% MeOH/CHCl3); [a]D +71 (c 0.53, MeOH);
(Found: C, 73.4; H, 5.1; N, 6.4. C13H11NO2 requires C, 73.2; H,
5.2; N, 6.6%); (Found: M+ 213.07876. C13H11NO2 requires
213.07898); dH (500 MHz, CD3COCD3) 4.13 (1 H, m, OH), 4.35
(1 H, m, OH), 4.42 (1 H, dd, J2,1 4.7, J2,3 4.8 , 2-H), 4.86 (1 H, d,
J1,2 4.7, 1-H), 6.54 (1 H, dd, J3,2 4.8, J3,4 10.1, 3-H), 6.77 (1 H, d,
J4,3 10.1, 4-H), 7.53 (1 H, dd, J7,8 8.1, J7,6 6.9, 7-H), 7.68 (1 H, dd,
J6,7 6.9, J6,5 8.5, 6-H), 7.90 (1 H, d, J8,7 8.1, 8-H), 7.95 (1 H, d, J5,6
8.5, 5-H), 8.28 (1 H, s, 9-H); dC (125 MHz, CD3COCD3) 66.6,
70.2, 126.3, 127.7, 127.9, 129.0, 129.1, 130.8, 132.1, 133.2,
136.3, 147.1, 153.0; m/z (EI): 213 (M+, 56%), 195 (23), 184 (100);
n 3369 cm21 (OH); ECD: l/nm 311 (De 1.036), 283 (De 21.079),
257 (De 4.644), 243 (De 6.421), 215 (De 4.647), 199.40 (De 0.573).
(1R,2S)-1,2,3,4-Tetrahydroacridine-1,2-diol 5.
cis-Dihydrodiol metabolite 4 (0.5 g, 2.35 mmol) was catalyti-
cally hydrogenated (H2, 10% Pd/C, 50 mg) in MeOH solution
(20 cm3) at atmospheric pressure and room temperature (4 h).
The catalyst was filtered off and the filtrate evaporated under
reduced pressure to yield (1R,2S)-1,2,3,4-tetrahydroacridine-
1,2-diol 5 as a semi-solid (0.420 g, 83%); [a]D +61 (c 1.00,
MeOH); (Found: M+ 215.0937. C13H13NO2 requires 215.0946);
dH (500 MHz, CDCl3) 2.12 (1 H, m, 3a-H), 2.32 (1 H, m, 3b-H),
3.11 (1 H, m, 4a-H), 3.36 (1 H, m, 4b-H), 4.28 (1 H, m, J2,1 3.5,
2-H), 4.93 (1 H, d, J1,2 3.5, 1-H), 7.49 (1 H, dd, J7,8 8.0, J7,6 7.1,
7-H), 7.68 (1 H, dd, J6,7 7.1, J6,5 8.4, 6-H), 7.79 (1 H, d, J8,7 8.0,
8-H), 8.00 (1 H, d, J5,6 8.4, 5-H), 8.30 (1 H, s, 9-H); dC (125 MHz,
CDCl3) 26.3, 29.5, 68.9, 70.2, 126.0, 127.2, 127.6, 128.4, 129.8,
137.0, 157.4, 162.6, 171.9; m/z (EI): 215 (M+, 71%), 198 (16), 186
(74), 168 (75), 143 (100); n 3435 cm21 (OH).
(1R,2S)-1,2-Diacetoxy-1,2,3,4-tetrahydroacridine 6.
cis-Tetrahydrodiol 5 (0.18 g, 0.84 mmol) was acetylated with
Ac2O (1.5 cm
3) in dry pyridine (0.7 cm3) solution by stirring the
mixture overnight at room temperature. Excess of pyridine was
removed under high vacuum, the residue treated with water
(10 cm3), and the aqueous mixture extracted with Et2O (36 15
cm3). The combined ether extract was dried (Na2SO4) and
concentrated to yield (1R,2S)-1,2-diacetoxy-1,2,3,4-tetrahydroa-
cridine 6 as a white crystalline solid (0.22 g, 88%); m.p. 84–85
uC (Et2O/hexane); [a]D 257 (c 0.85, MeOH); (Found: M
+
299.1150. C17H17NO4 requires 299.1158); dH (500 MHz,
CDCl3) 2.05 (3 H, s, OCOMe), 2.15 (3 H, s, OCOMe), 2.20 (1
H, m, J3a,2 3.1, 3a-H), 2.44 (1 H, m, 3b-H), 3.23 (1 H, m, 4a-H),
3.40 (1 H, m, 4b-H), 5.43 (1 H, m, J2,1 3.3, J2,3a 3.1, 2-H), 6.32 (1
H, d, J1,2 3.3, 1-H), 7.51 (1 H, dd, J7,8 8.1, J7,6 7.0, 7-H), 7.72 (1 H,
dd, J6,7 7.0, J6,5 8.5, 6-H), 7.79 (1 H, d, J8,7 8.1, 8-H), 8.02 (1 H, d,
J5,6 8.5, 5-H), 8.12 (1 H, s, 9-H); dC (125 MHz, CDCl3) 19.6, 19.7,
22.1, 28.8, 67.8, 68.3, 124.9, 125.3, 125.4, 126.4, 127.0, 128.9,
135.9, 146.5, 155.6, 169.0, 169.2; m/z (EI): 299 (M+, 69%), 197
(100); n 1741 cm21 (CLO), 1421.
Oxidative degradation of diacetate 6. Ruthenium(II) oxide
hydrate (2 mg) was added to a biphasic mixture of the
diacetate 6 (0.1 g, 0.33 mmol) and NaIO4 (3.4 g, 16 mmol) in a
mixture of CCl4 (2 cm
3), MeCN (2 cm3) and water (3 cm3). After
stirring the reaction mixture for 4 days at ambient tempera-
This journal is  The Royal Society of Chemistry 2013 RSC Adv., 2013, 3, 10944–10955 | 10951
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ture, dilute HCl (20 cm3, 1.5 M) was added and the reaction
mixture extracted with EtOAc (3 6 30 cm3). The combined
extract was washed with water, dried (Na2SO4), and concen-
trated under reduced pressure to yield a crude mixture of two
dicarboxylic acids. The mixture was dissolved in MeOH (5 cm3)
and treated (0 uC, 0.5 h) with excess of freshly prepared
ethereal diazomethane solution. The solvents were evaporated,
in a fume hood under a stream of nitrogen, and the crude
methyl esters separated by column chromatography (25% A
75% Et2O/hexane) to yield dimethyl (5R,6S)-5,6-di(acetoxy)-
5,6,7,8-tetrahydro-2,3-quinolinedicarboxylate 9, the more polar
major compound (21 mg, 17%), and (2S,3S)-dimethyl-(2,3-
diacetoxy)-adipate 10 (9 mg, 9.3%) as the less polar minor
compound.
Dimethyl (5R,6S)-5,6-diacetoxy-5,6,7,8-tetrahydro-2,3-quino-
linedicarboxylate 9. White crystalline solid; m.p. 115–117 uC
(from CHCl3); [a]D 253 (c 0.66, MeOH); (Found: C, 55.7; H, 5.1;
N, 3.9. C17H19NO8 requires C, 55.9; H, 5.2; N, 3.8%); (Found:
M+ 365.1105. C17H19NO8 requires 365.1111); dH (500 MHz,
CDCl3) 2.04 (3 H, s, OCOMe), 2.15 (3 H, s, OCOMe), 2.16 (1 H,
m, J7a,6 3.1, 7a-H), 2.35 (1 H, m, 7b-H), 3.11 (1 H, m, 8a-H),
3.25(1 H, m, 8b-H), 3.92 (3 H, s, CO2Me), 3.99 (3 H, s, CO2Me),
5.42 (1 H, m, J6,5 3.4, J6,7a 3.1, 6-H), 6.13 (1 H, d, J5,6 3.4, 5-H),
8.11 (1 H, s, 4-H); dC (125 MHz, CDCl3) 21.3 (62), 23.6, 29.5,
53.3, 53.6, 68.3, 69.0, 123.8, 130.4, 138.8, 151.4, 160.6, 165.5,
167.2, 170.6, 170.7; m/z (EI): 365 (M+, 21%), 43 (100); n 1746
cm21 (CLO).
(2S,3S)-Dimethyl-(2,3-diacetoxy)-adipate 10. Colourless oil;
[a]D 214 (c 0.74, CHCl3) (lit.
6 214.1, CHCl3); dH (500 MHz,
CDCl3) 1.97 (1 H, m, CH2), 2.07 (3 H, s, OCOMe), 2.06–2.15 (1
H, m, CH2), 2.18 (3 H, s, OCOMe), 2.37 (2 H, m, CH2), 3.68 (3
H, s, CO2Me), 3.79 (3 H, s, CO2Me), 5.30 (2 H, m, 2-H and 3-H);
m/z (EI): 259 (M+-OMe, 5%), 217 (M+-COMe, 16); n 1735 cm21
(CLO).
(b) Biotransformation of dictamnine 12
A small scale biotransformation of dictamnine 12 (60 mg),
using S. yanoikuyae B8/36, followed by extraction with EtOAc
yielded a mixture of two dihydrodiol metabolites, (5R,6S)-4-
methoxy-5,6-dihydrofuro[2,3-b]quinoline-5,6-diol 16 and
(7S,8R)-4-methoxy-7,8-dihydrofuro-[2,3-b]quinoline-7,8-diol 17.
These diols were separated by PLC (7% MeOH/CHCl3). A
repeat larger scale biotransformation of dictamnine 12 (0.6 g,
3.02 mmol), using S. yanoikuyae B8/36, yielded a mixture of
three compounds, diol 16 (8 mg, 1.1%), diol 17 (0.143 g, 20%)
and 3-(1,2-dihydroxyethyl)-4-methoxy-1,2-dihydro-2-quinoli-
none 23 (7 mg, 1.0%).
(5R,6S)-4-Methoxy-5,6-dihydrofuro[2,3-b]quinoline-5,6-diol
16. White solid (2 mg, 3%); m.p. 157–159 uC; Rf 0.26 (7%
MeOH/CHCl3); [a]D 2111 (c 0.19, MeOH); (Found M
+ 233.0694.
C12H11NO4 requires 233.0688); dH (500 MHz, CDCl3) 4.32 (3 H,
s, OMe), 4.63 (1 H, m, 6-H), 5.14 (1 H, d, J5,6 5.3, 5-H), 6.19 (1 H,
ddd, J7,8 10.0, J7,6 = J7,5 = 1.9, 7-H), 6.57 (1 H, dd, J8,7 10.0, J8,6
2.6 8-H), 6.98 (1 H, d, J3,2 2.5, 3-H), 7.60 (1 H, d, J2,3 2.5, 2-H); dC
(125 MHz, CDCl3) 58.9, 63.8, 69.7, 105.4, 105.8, 114.1, 128.4,
136.4, 143.0, 147.9, 158.9, 164.4; m/z (EI): 233 (M+, 6%), 215 (9),
43 (100); ECD: l/nm 286 (De 4.808), 245 (De 25.670), 229 (De
0.415), 216 (De 23.007), 204 (De 1.004).
(7S,8R)-4-Methoxy-7,8-dihydrofuro[2,3-b]quinoline-7,8-diol
17. White solid (41 mg, 29%); m.p. 185–187 uC (MeOH/CHCl3);
Rf 0.3 (7% MeOH/CHCl3); [a]D +94 (c 0.78, MeOH); (Found: M
+
233.0689. C12H11NO4 requires 233.0688); dH (500 MHz, CDCl3)
4.28 (3 H, s, OMe), 4.45 (1 H, dd, J7,8 5.0, J7,6 5.0, 7-H), 4.78 (1
H, d, J8,7 5.0, 8-H), 6.17 (1 H, dd, J6,5 9.8, J6,7 5.0, 6-H), 6.98 (1 H,
d, J3,2 2.5, 3-H), 7.02 (1 H, d, J5,6 9.8, 5-H), 7.57 (1 H, d, J2,3 2.5,
2-H); dC (125 MHz, CDCl3) 58.8, 64.5, 71.1, 105.5, 106.0, 111.7,
123.8, 124.2, 142.2, 151.7, 156.7, 163.1; m/z (EI): 233 (M+, 61%),
215 (9), 204 (100); ECD: l/nm 275.60 (De 20.425), 246.10 (De
2.722), 205.90 (De 20.272).
3-(1,2-Dihydroxyethyl)-4-methoxy-1,2-dihydro-2-quinolinone
23. Brown solid (1.1 mg, 1.6%); m.p. 137–140 uC (decomp.); Rf
0.20 (7% MeOH/CHCl3); [a]D +8.8 (c 0.68, MeOH); (Found: M
+
235.0840. C12H13NO4 requires 235.0845); dH (500 MHz, CDCl3)
3.82 (1 H, dd, J2,29 11.1, J2,1 4.4, 2-H), 3.97 (1 H, dd, J29,2 11.1,
J29,1 7.4, 29-H), 4.04 (3 H, s, OMe), 5.15 (1 H, dd, J1,2 4.4, J1,29 7.4,
1-H), 7.30 (1 H, dd, J6,7 = J6,5 = 7.9, 6-H), 7.35 (1 H, d, J8,7 8.2,
8-H), 7.57 (1H, dd, J7,8 8.2, J7,6 7.9, 7-H), 7.81 (1 H, d, J5,67.9,
5-H), 11.68 (1 H, br s, NH); dC (75 MHz, CDCl3) 62.9, 66.0, 69.0,
116.3, 116.8, 119.7, 123.4, 123.5, 131.5, 137.7, 163.7, 166.2; m/z
(EI): 235 (M+, 4%), 204 (20), 122 (83), 105 (100), 77 (80), 51 (54),
43 (71).
(c) Biotransformation of 4-chlorofuro[2,3-b]quinoline 11
A small-scale biotransformation on 4-chlorofuro[2,3-b]quino-
line 11 (0.8 g, 3.93 mmol), using S. yanoikuyae B8/36, followed
by concentration of the aqueous portion under reduced
pressure and extraction of the concentrate by ethyl acetate
yielded a mixture of products. PLC purification of the mixture
(6% MeOH/CHCl3) gave (7S,8R)-4-chloro-7,8-dihydrofuro[2,3-
b]quinoline-7,8-diol 15 (0.35 g, 38%); Rf 0.6 (6% MeOH/CHCl3),
(5R,6S)-4-chloro-5,6-dihydrofuro[2,3-b]quinoline-5,6-diol 14 (93
mg, 10%); Rf 0.5 (6% MeOH/CHCl3) and 4-chloro-3-(1,2-
dihydroxyethyl)-1,2-dihydro-2-quinolinone 20 (23 mg, 2.5%);
Rf 0.4 (6% MeOH/CHCl3).
(7S,8R)-4-Chloro-7,8-dihydrofuro[2,3-b]quinoline-7,8-diol
15. Brown crystalline solid (0.35 g, 38%); m.p. 121–123 uC
(decomp., CHCl3/hexane); [a]D +138.1 (c 0.53, CHCl3); (Found:
M+ 237.0201. C11H8NO3 requires 237.0193); dH (500 MHz,
CDCl3) 4.49 (1 H, dd, J7,8 4.8, J7,6 5.2, 7-H), 4.81 (1 H, d, J8,7 4.8,
8-H), 6.34 (1 H, dd, J6,7 5.2, J6,5 9.9, 6-H), 6.85 (1 H, d, J3,2 2.4,
3-H), 7.05 (1 H, d, J5,6 9.9, 5-H), 7.66 (1 H, d, J2,3 2.4, 2-H); dC
(125 MHz, CDCl3) 63.8, 70.3, 104.2, 117.6, 120.3, 123.5, 127.5,
133.6, 144.0, 150.9, 159.1; m/z (EI): 239 (M+, 37Cl, 14%), 237
(M+, 43), 219 (M+-H2O, 15), 208 (M
+-CHO, 75), 199 (100), 190
(80), 184 (55), 156 (49), 149 (29), 128 (28); ECD: l/nm 316 (De
20.31), 316 (De 20.27), 253 (De 4.12), 235 (De 3.34), 207 (De
22.07).
(5R,6S)-4-Chloro-5,6-dihydrofuro[2,3-b]quinoline-5,6-diol
14. Brown crystalline solid (93 mg, 10%); m.p. 172–174 uC
(decomp.); [a]D +189 (c 0.41, MeOH); (Found M
+ 237.0199.
C11H8ClNO3 requires 237.0193); dH (500 MHz, CDCl3) 4.72 (1
H, br s, 6-H), 5.21 (1 H, dd, J5,6 5.1, J5,7 1.7, 5-H), 6.23 (1 H, ddd,
J7,8 10, J7,6 = J7,5 = 1.7, 7-H), 6.64 (1 H, dd, J8,7 10, J8,6 2.7, 8-H),
6.86 (1 H, d, J3,2 2.5, 3-H), 7.72 (1 H, d, J2,3 2.5, 2-H); dC (125
MHz, CDCl3) 66.1, 69.7, 105.3, 118.1, 123.5, 128.17, 136.8,
137.68, 145.8, 148.2, 161.7; m/z (EI): 237 (M+, 35Cl, 5%), 221
10952 | RSC Adv., 2013, 3, 10944–10955 This journal is  The Royal Society of Chemistry 2013
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(72), 219 (100), 191 (18), 156 (80); ECD: l/nm 316 (De 3.07), 306
(De 3.98), 290 (De 3.70), 246 (De 25.26), 217 (De 26.16), 201(De
0.61).
4-Chloro-3-(1,2-dihydroxyethyl)-1,2-dihydro-2-quinolinone
20. Brown solid (23 mg, 2%); m.p. 184–186 uC (decomp.); [a]D
25.1 (c 0.43, MeOH); (Found: M+-CH2OH 208.0157.
C10H7ClNO2 requires 208.0165); dH (500 MHz, CD3OD) 3.76
(1 H, dd, J2,29 11.3, J2,1 5.6, 2-H), 3.87 (1 H, dd, J29,2 11.3, J29,1 7.2,
29-H), 4.51 (2 H, br s, OH), 5.20 (1 H, dd, J1,2 5.6, J1,29 7.2, 1-H),
7.32 (2 H, m, 6-H, 8-H), 7.57 (1 H, m, 7-H), 8.00 (1 H, dd, J5,6
8.2, J5,7 1.1, 5-H); dC (125 MHz, CD3OD) 65.8, 74.2, 117.1, 120.2,
125.0, 127.0, 129.6, 133.2, 138.7, 144.8, 164.0; m/z (EI): 210 (M+,
37Cl-CH2OH, 31%), 208 (100), 162 (15), 89 (13), 32 (16).
(7S,8R)-4-Methoxy-5,6,7,8-tetrahydrofuro[2,3-b]quinoline-
7,8-diol 32. A solution of dictamnine 7,8-diol 17 (0.15 g, 0.64
mmol) in MeOH (10 cm3) containing 3% Pd/C (15 mg) was
stirred (1 h) under hydrogen atmosphere at atmospheric
pressure. The reaction mixture was filtered and the solvent
removed under reduced pressure to yield the crude product as
a brown oil. Purification of the crude product by PLC (4%
MeOH/CHCl3), afforded the tetrahydro cis-diol 32 as a white
solid (0.115 g, 76%); m.p. 149–151 uC (from EtOAc); Rf 0.5 (4%
MeOH/CHCl3); [a]D 225 (c 0.39, CHCl3); (Found: M
+ 235.0843.
C12H13NO4 requires 235.0844); dH (500 MHz, CDCl3) 1.82–1.89
(1 H, m, 69-H), 2.24–2.28 (1 H, m 6-H), 2.64 (1 H, br s, OH), 2.76
(1 H, m, 59-H), 2.86 (1 H, m, 5-H), 4.20 (3 H, s, OMe), 4.35 (1 H,
m, 7-H), 4.70 (1 H, d, J8,7 3.3, 8-H), 6.95 (1 H, d, J3,2 2.6, 3-H),
7.53 (1 H, d, J2,3 2.6, 2-H); dC (125 MHz, CDCl3) 18.3, 25.0 , 58.6,
66.74, 70.8, 104.9, 106.5, 115.2, 142.2, 151.0, 158.5, 162.8; m/z
(EI): 235 (M+, 30%), 206 (100), 188 (92), 163 (94), 133 (35).
(7S,8S)-8-Bromo-4-methoxy-5,6,7,8-tetrahydrofuro[2,3-b]qui-
nolin-7-yl acetate 33. cis-Tetrahydrodiol 32 (0.1 g, 0.43 mmol)
was converted into bromoacetate 33, using the first step of the
method described for the synthesis of arene oxide 2.
Purification of the crude product by PLC (25% EtOAc/hexane)
afforded a pure sample of bromoacetate 33 as a pale yellow oil
(0.13 g, 90%); Rf 0.25 (25% EtOAc/hexane); [a]D 237.5 (c 1.16,
CHCl3); (Found: M
+ 339.0121. C14H14BrNO4 requires
339.0106); dH (500 MHz, CDCl3) 1.99 (3 H, s, OCOMe), 2.14–
2.18 (1 H, m, 69-H), 2.51–2.59 (1 H, m, 6-H), 2.72–2.80 (1 H, m,
59-H), 2.93–2.98 (1 H, ddd, J 5,59 17.5, J 5,69 6.7, J 5,6 2.1, 5-H),
4.27 (3 H, s, OMe), 5.30 (1-H, dd, J8,7 3.0, J8,6 1.5, 8-H), 5.54 (1
H, m, 7-H), 6.95 (1 H, d, J3,2 2.6, 3-H), 7.58 (1 H, d, J2,3 2.6, 2-H);
dC (125 MHz, CDCl3) 17.7, 21.1, 21.3, 48.1, 58.6, 72.4, 104.8,
106.1, 115.7, 143.2, 147.7, 158.4, 162.8, 170.1; m/z (EI): 341 (M+,
81Br, 30%), 339 (M+, 79Br, 29), 281 (20), 279 (20), 218 (50), 200
(33), 101 (61), 59 (65), 43 (100).
(d) Chemoenzymatic synthesis of (1R,2S)-1,2-epoxy-1,2-
dihydroacridine (acridine 1,2-oxide) 2
To a stirred solution of cis-dihydrodiol 4 (0.1 g, 0.47 mmol) in
dry MeCN (4 cm3) was added, at 0 uC, 1-bromocarbonyl-1-
methylethyl acetate (0.109 g, 0.52 mmol). The reaction mixture
was stirred (1.5 h) at room temperature, diluted with Et2O (30
cm3) and the solution washed thoroughly with 5% aqueous
NaHCO3 solution (15 cm
3). The organic layer was dried
(Na2SO4) and concentrated to yield an inseparable mixture of
bromoacetates 25 and 26 in which bromoacetate 25 was the
major component (0.12 g, 81%); (Found: M+ 317.0061.
C15H12NO2
79Br requires 317.0051).
(1R,2R)-1-Acetoxy-2-bromo-1,2-dihydroacridine 25. dH (500
MHz, CDCl3) 1.99 (3 H, s, OCOMe), 4.93 (1 H, dd, J2,1 2.5,
J2,3 5.7, 2-H), 6.35 (1 H, d, J1,2 2.5, 1-H), 6.62 (1 H, dd, J3,2 5.7,
J3,4 9.8, 3-H), 7.01 (1 H, d, J4,3 9.8, 4-H), 7.55–8.09 (4 H, m,
Aromatic), 8.27 (1 H, s, 9-H). (1S,2S)-1-Bromo-2-acetoxy-1,2-
dihydroacridine 26. dH (500 MHz, CDCl3) 2.00 (3 H, s, OCOMe),
5.51 (1 H, d, J1,2 2.5, 1-H), 5.73(1 H, dd, J2,1 2.5, J2,3 5.4, 2-H),
6.58 (1 H, dd, J3,2 5.4, J3,4 9.7, 3-H), 7.16 (1 H, d, J4,3 9.7, 4-H),
7.54–8.09 (4 H, m, Aromatic), 8.13 (1 H, s, 9-H); m/z (EI): 317
(M+, 79Br, 41%), 238 (80), 196 (100).
A cooled solution (0 uC) of bromoacetates 25 and 26 (0.1 g,
0.31 mmol) in dry Et2O (10 cm
3) was treated with NaOMe (24
mg, 0.44 mmol). The reaction mixture was stirred overnight at
room temperature. After addition of water (10 cm3) to the
reaction mixture, it was extracted with Et2O (3 6 15 cm
3), the
combined ether extract dried (Na2SO4) and the solvent
evaporated under reduced pressure to yield (1R,2S)-acridine-
1,2-oxide 2 as a light brown solid (51 mg, 83%); m.p. 136–137
uC (CHCl3/hexane) (lit.
9 136–138 uC); [a]D +30 (c 0.49, CHCl3)
(lit.9 +22, CHCl3); (Found: M
+ 195.0689. C13H9NO requires
195.0684); dH (500 MHz, CDCl3) 4.08 (1 H, dd, J2,1 3.8, J2,3 6.1,
2-H), 4.55 (1 H, d, J1,2 3.8, 1-H), 6.78 (1 H, dd, J3,2 6.1, J3,4 10.0,
3-H), 7.03 (1 H, d, J4,3 10.0, 4-H), 7.51 (1 H, dd, J6,7 7.0, J6,5 8.2,
6-H), 7.67 (1 H, dd, J7,6 7.0, J7,8 8.6, 7-H), 7.78 (1 H, J8,7 8.6, 8-H),
8.02 (1 H, J5,6 8.2, 5-H), 8.30 (1 H, s, 9-H); dC (125 MHz, CDCl3)
52.4, 56.7, 126.1, 127.4, 127.8, 127.9, 129.8, 130.1, 131.9, 134.5,
137.9, 148.6, 151.8; m/z (EI): 195 (M+, 84%), 167 (100).
(e) Chemoenzymatic synthesis of dictamnine 7,8-oxide 27 and
4-methoxyfuro[2,3-b]quinoline-7,8-diol 29
Dictamnine 7,8-oxide 27. To a solution of bromoacetate 33
(0.16 g, 0.47 mmol) in CCl4 (4 cm
3) was added NBS (93 mg,
0.52 mmol) and AIBN (ca. 2 mg). The stirred reaction mixture
was heated to 65 uC, under nitrogen using a heat lamp, until
all the NBS had reacted. The cooled reaction mixture was
filtered and the filtrate concentrated under reduced pressure.
The crude dibromoacetate 34 obtained was used immediately,
without purification, for the next step.
The synthesis of dictamnine 7,8-oxide 27 from the crude
dibromoacetate 34 (0.15 g, 0.36 mmol) was carried out
following the second step of the method described for the
synthesis of arene oxide 2, using dry THF (3 cm3) instead of
Et2O as a solvent. The crude sample of 7,8-oxide 27 crystallized
out of ether/hexane solution to give a pure sample as a light
brown solid (43 mg, 56%); m.p. 125–127 uC (from CHCl3/
hexane); (Found: M+ 215.0586. C12H9NO3 requires 215.0582);
[a]D +93.1 (c 0.36, CHCl3); dH (500 MHz, CDCl3) 4.18 (1 H, ddd,
J7,8 3.71, J7,6 3.66, J7,5 1.84, 7-H), 4.30 (3 H, s, OMe), 4.65 (1 H,
d, J8,7 3.84, 8-H), 6.37 (1 H, dd, J6,5 9.86, J6,7 3.66, 6-H), 7.01 (1
H, d, J3,2 2.57, 3-H), 7.20 (1 H, dd, J5,6 9.86, J5,7 1.8, 5-H), 7.62 (1
H, d, J2,3 2.57, 2-H); dC (125 MHz, CDCl3) 54.4, 58.4, 58.9, 104.6,
105.3, 106.6, 113.5, 122.6, 124.4, 143.0, 148.8, 157.4; m/z (EI):
215 (M+, 100%), 200 (57), 172 (30), 83 (27); ECD: l/nm 322 (De
0.747), 288 (De 0.867), 241 (De 7.87), 203 (De 26.38).
4-Methoxyfuro[2,3-b]quinoline-7,8-diol 29. A cooled solution
(215 uC) of skimmianine 13 (0.5 g, 1.93 mmol) in dry CH2Cl2
(15 cm3) was treated, drop-wise, with a solution of boron
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tribromide in CH2Cl2 (1 M, 4.8 cm
3). After leaving the reaction
mixture stirred, at room temperature overnight, it was cooled
to 260 uC and water (5 cm3) was added and the mixture
allowed to warm up to room temperature. The CH2Cl2 layer
was separated and the remaining aqueous solution was
extracted with EtOAc (2 6 10 cm3). The combined organic
extract was dried (Na2SO4) and concentrated, under reduced
pressure, to yield the crude catechol 29. Crystallisation from
MeOH furnished catechol 29 as an off-white coloured solid
(0.38 g, 85%); m.p. 211 uC (from MeOH); Rf 0.1 (50% EtOAc/
hexane); (Found: M+, 231.0523. C12H9NO4 requires M
+,
231.0532); dH (500 MHz, CD3COCD3) 4.39 (3 H, s, OMe), 6.99
(1 H, d, J6,5 9.1, 6-H), 7.23 (1 H, d, J2,3 2.8, 2-H), 7.52 (1 H, d, J5,6
9.1, 5-H), 7.66 (1 H, d, J3,2 2.8, 3-H).
(f) Chemoenzymatic synthesis of furoquinoline alkaloids 30,
31, 36, 37, 38 and 40
Robustine 30. Dihydrodiol 17 (10 mg, 0.04 mmol), dissolved
in CHCl3 solution, was aromatised by the addition of two
drops of TFA. The acidic solution was concentrated after
adding excess of ammonium hydroxide to yield robustine 17
as a light brown solid (9 mg, 98%); m.p. 147 uC (lit.13b 148–149
uC); dH (300 MHz, CDCl3) 4.43 (3 H, s, OMe), 7.17 (1H, d, J3,2
2.8, 3-H), 7.20 (1 H, d, J7,6 7.8, 7-H), 7.38 (1 H, dd, J6,7 = J6,5 =
7.8, 6-H), 7.63 (1 H, d, J2,3 2.8, 2-H), 7.79 (1 H, d, J5,6 7.8, 5-H);
m/z (EI): 215 (M+, 100%), 200 (59).
c-Fagarine 31. Robustine 30 (5 mg, 0.023 mmol) was
dissolved in MeOH (1 cm3) and treated (0 uC) with an excess
of ethereal solution of diazomethane. The solvents were
evaporated under a stream of nitrogen to yield the title
compound 31 (4.2 mg, 79%); m.p. 142–143 uC (lit.13c 141 uC);
dH (500 MHz, CDCl3) 4.09 (3 H, s, OMe), 4.46 (3 H, s, OMe),
7.01 (1 H, d, J7,6 7.8, H-7), 7.09 (1 H, d, J3,2 2.7, H-3), 7.35 (1 H,
dd, J6,5 8.3 J6,7 7.8, H-6), 7.65 (1 H, d, J2,3 2.7, H-2), 7.85 (1 H, d,
J5,6 8.3, H-5); dC (125 MHz, CDCl3): 29.6, 56.0, 59.0, 104.5,
107.7, 114.1, 118.9, 123.2, 123.4, 129.7, 143.9, 154.5, 157.2; m/z
(EI): 229 (M+, 100%), 214 (18).
Haplopine 36. Catechol 29 (50 mg, 0.20 mmol) was treated
(0 uC) with an excess of ethereal diazomethane solution. After
leaving the reaction mixture for five minutes, excess of reagent
was removed by the addition of a few drops of acetic acid. The
crude product, obtained after removal of ether, was purified by
PLC (50% EtOAc/hexane), to give haplopine 36 as a white solid
(27 mg, 55%); m.p. 203–205 uC (from EtOAc–hexane) (lit.13d
203–204 uC); Rf 0.2 (50% EtOAc/hexane); dH (500 MHz, CDCl3)
4.22 (3 H, s, OMe), 4.43 (3 H, s, OMe), 7.05 (1 H, d, J3,2 2.8,
3-H), 7.17 (1 H, d, J6,5 9.2, 6-H), 7.58 (1 H, d, J2,3 2.8, 2-H), 7.97
(1 H, d, J5,6 9.2, 5-H).
4-Methoxy-8-[(3-methyl-2-butenyl)oxy]furo[2,3-b]quinolin-7-
ol 37. A mixture of catechol 29 (50 mg, 0.22 mmol), anhydrous
K2CO3 (50 mg) and 1-chloro-3-methyl-but-2-ene (0.03 cm
3, 0.24
mmol) in dry acetone (5 cm3) was heated under reflux (2 h).
The solvent was removed under reduced pressure, the residue
taken up in EtOAc (10 cm3), the solution washed with water (5
cm3) and dried (Na2SO4). Removal of solvent under reduced
pressure yielded the crude product which was purified by
multiple elution PLC (30% EtOAc/hexane) to furnish the title
compound 37 as a white solid (46 mg, 70%); m.p. 152–153 uC
(from EtOAc/hexane); Rf 0.2 (50% EtOAc/hexane); (Found: M
+,
299.1166. C17H17NO4 requires M
+, 299.1158); dH (500 MHz,
CDCl3) 1.62 (3 H, s, Me), 1.75 (3 H, s, Me), 4.43 (3 H, s, OMe),
5.01 (2 H, d, J29,39, 7.5, 29-H), 5.60 (1 H, t, J39,29 4.5, 39-H), 7.05 (1
H, d, J3,2 2.8, 3-H), 7.15 (1 H, d, J6,5 9.2, 6-H), 7.57 (1 H, d, J2,3
2.8, 2-H), 7.95 (1 H, d, J5,6 9.2, 5-H); m/z (EI): 299 (M
+, 20%), 231
(100).
iso-Haplopine-3,39-dimethylallylether 38. 4-Methoxy-8-[(3-
methyl-2-butenyl)oxy]furo[2,3-b]quinolin-7-ol 37 (20 mg, 0.067
mmol) was treated with an excess of diazomethane as
described earlier. The crude methylated product was purified
by PLC to give compound 38 as a white solid (19 mg, 90%);
m.p. 124–125 uC (from CH2Cl2) (lit.
13e 120–121.5 uC); Rf 0.4
(40% EtOAc/hexane); (Found: M+, 313.1312. C18H19NO4
requires 313.1314); dH (500 MHz, CDCl3) 1.66 (3 H, s, Me),
1.74 (3 H, d, Me), 4.00 (3 H, s, OMe), 4.43 (3 H, s, OMe), 4.84 (2
H, d, J19,29 7.2, 19-H), 5.73 (1 H, t, J29,19,7.2, H-29), 7.04 (1 H, d,
J3,2 2.8, 3-H), 7.22, d, J6,5 9.4, 6-H), 7.58 (1 H, d, J2,3 2.80, 2-H),
8.00 (1 H, d, J5,6 9.4, 5-H); m/z (EI): 313 (M
+, 20%).
Pteleine 40. cis-Dihydrodiol 16 (7 mg, 0.004 mmol) was
dissolved in CDCl3 in an NMR tube and a drop of TFA added to
the solution. The tube was kept at 50 uC until the aromatiza-
tion of diol 16 was complete (1H-NMR analysis). After removal
of solvent the aromatized product was treated with excess of
diazomethane and the crude product obtained was purified by
PLC (40% EtOAc/hexane) to afford pure pteleine 40 as a white
solid (3 mg, 77%); m.p. 132–134 uC (lit.13f 134.5 uC); Rf 0.4
(40% EtOAc/hexane); dH (500 MHz, CDCl3) 3.95 (3 H, s, Me),
4.60 (3 H, s, Me), 7.07 (1 H, d, J3,2 2.8, 3-H), 7.36 (1 H, dd, J7,8
9.15, J7,5 2.95, 7-H), 7.53 (1 H, d, J8,7 2.95, 8-H), 7.63 (1 H, d, J2,3
2.8, 2-H), 7.92 (1 H, d, J8,7 9.15, 8-H).
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